COMMUNIQUÉS West-GlobeNewswire

Lexicon Pharmaceuticals Announces Topline Phase 1 Clinical Results for LX2761 in Diabetes
20/12/2018
THE WOODLANDS, Texas, Dec. 20, 2018 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced topline results from Phase 1 clinical studies of LX2761, an oral sodium-glucose cotransporter type 1 [...]
Form 8 (DD) - Gail Fosler
20/12/2018
FORM 8 (DD) PUBLIC DEALING DISCLOSURE BY A PARTY TO AN OFFER OR PERSON ACTING IN CONCERT (INCLUDING DEALINGS FOR THE ACCOUNT OF DISCRETIONARY INVESTMENT CLIENTS) Rules 8.1, 8.2 and 8.4 of the Takeover Code (the “Code”) [...]
Supernus Announces Positive Results from Phase III Study For SPN-812 in Adolescents with ADHD
20/12/2018
Met primary endpoint with robust statistical significance Third positive Phase III study for SPN-812 in patients with ADHD Showed efficacy on both hyperactivity/impulsivity and inattention subscales with statistical [...]
Bellicum Pharmaceuticals Announces Appointment of Judith Klimovsky, M.D., to Board of Directors
20/12/2018
HOUSTON, Dec. 20, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today [...]
Apellis Pharmaceuticals Provides Update on Its Phase 3 Program for Patients with Geographic Atrophy
20/12/2018
Phase 3 geographic atrophy program enrollment timeline currently unchanged; program enrollment is expected to restart in Q2 2019 and enrollment completion is expected in Q1 2020 CRESTWOOD, Ky. and WALTHAM, Mass., Dec. [...]
Amicus Therapeutics Announces First Patient Dosed in Phase 3 PROPEL Pivotal Study of AT-GAA in Patients with Pompe Disease
20/12/2018
Global Study to Assess AT-GAA Compared to Standard-of-Care Enzyme Replacement Therapy (ERT) over 52 Weeks CRANBURY, N.J., Dec. 20, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a global biotechnology [...]
FibroGen Announces Positive Topline Results from Three Global Phase 3 Trials of Roxadustat for Treatment of Anemia in Patients with Chronic Kidney Disease
20/12/2018
Primary efficacy endpoints met in all three studies: non-dialysis, incident dialysis, and stable dialysis studies SAN FRANCISCO, Dec. 20, 2018 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a leading [...]
Nabriva Therapeutics Submits New Drug Applications to U.S. Food and Drug Administration for Intravenous and Oral Lefamulin to Treat Community-Acquired Bacterial Pneumonia in Adults
20/12/2018
DUBLIN, Ireland, Dec. 20, 2018 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a clinical-stage biopharmaceutical company engaged in the research and development of innovative anti-infective agents to treat [...]
miRagen Therapeutics to Present New Cobomarsen Clinical Trial Data for Adult T-Cell Leukemia/Lymphoma and Cutaneous T-Cell Lymphoma at the 11th Annual T-Cell Lymphoma Forum
20/12/2018
BOULDER, Colo., Dec. 20, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced [...]
Form 8 (DD) - Steven Gillis
20/12/2018
FORM 8 (DD) PUBLIC DEALING DISCLOSURE BY A PARTY TO AN OFFER OR PERSON ACTING IN CONCERT (INCLUDING DEALINGS FOR THE ACCOUNT OF DISCRETIONARY INVESTMENT CLIENTS) Rules 8.1, 8.2 and 8.4 of the Takeover Code (the “Code”) [...]
Form 8 (DD) - Sara Mathew
20/12/2018
FORM 8 (DD) PUBLIC DEALING DISCLOSURE BY A PARTY TO AN OFFER OR PERSON ACTING IN CONCERT (INCLUDING DEALINGS FOR THE ACCOUNT OF DISCRETIONARY INVESTMENT CLIENTS) Rules 8.1, 8.2 and 8.4 of the Takeover Code (the “Code”) [...]
New Data on AlloSure Confirms Its Clinical Utility in Repeat Kidney Transplant Recipients
20/12/2018
Study published in the American Journal of Transplantation BRISBANE, Calif., Dec. 20, 2018 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading molecular diagnostics company focused on the discovery, development [...]
iCAD, Inc. Announces $7.0 Million Private Placement of Unsecured Subordinated Convertible Debentures
20/12/2018
Added Funds to support global commercialization of cancer detection capability and cancer therapy technology NASHUA, N.H., Dec. 20, 2018 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology company [...]
Form 8 (DD) - Albert Stroucken
20/12/2018
FORM 8 (DD) PUBLIC DEALING DISCLOSURE BY A PARTY TO AN OFFER OR PERSON ACTING IN CONCERT (INCLUDING DEALINGS FOR THE ACCOUNT OF DISCRETIONARY INVESTMENT CLIENTS) Rules 8.1, 8.2 and 8.4 of the Takeover Code (the “Code”) [...]
Form 8 (DD) - Susan Kilsby
20/12/2018
FORM 8 (DD) PUBLIC DEALING DISCLOSURE BY A PARTY TO AN OFFER OR PERSON ACTING IN CONCERT (INCLUDING DEALINGS FOR THE ACCOUNT OF DISCRETIONARY INVESTMENT CLIENTS) Rules 8.1, 8.2 and 8.4 of the Takeover Code (the “Code”) [...]
Form 8 (DD) - David Ginsburg
20/12/2018
FORM 8 (DD) PUBLIC DEALING DISCLOSURE BY A PARTY TO AN OFFER OR PERSON ACTING IN CONCERT (INCLUDING DEALINGS FOR THE ACCOUNT OF DISCRETIONARY INVESTMENT CLIENTS) Rules 8.1, 8.2 and 8.4 of the Takeover Code (the “Code”) [...]
Avivagen Announces Proposed Extension of Warrants
20/12/2018
OTTAWA, Dec. 20, 2018 (GLOBE NEWSWIRE) -- Avivagen Inc. (TSXV:VIV) (“Avivagen” or “Corporation”), a world leader in natural alternatives to antibiotics with its OxC-beta™ technology, today announced that it will be [...]
Eton Pharmaceuticals Reports Third Quarter Results and Business Update
20/12/2018
Licensed High-Value Injectable Product Candidate Successfully Completed Initial Public Offering DEER PARK, Ill., Dec. 20, 2018 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a specialty pharmaceutical [...]
ADMA to Host Conference Call to Discuss Recent Regulatory Update on BIVIGAM® PAS Submissions
20/12/2018
Call Scheduled for 9am Eastern Time RAMSEY, N.J. and BOCA RATON, Fla., Dec. 20, 2018 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and [...]

Pages